Neos Therapeutics, Inc. (NEOS)

[guchu]

Neos Therapeutics, Inc. (NEOS) Stock Rating Upgraded by Zacks Investment Research
January 12th, 2017 - By Scott Moore - 0 comments
Neos Therapeutics logoNeos Therapeutics, Inc. (NASDAQ:NEOS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “

Separately, BMO Capital Markets reissued a “buy” rating and issued a $15.00 target price on shares of Neos Therapeutics in a research report on Tuesday, September 20th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Neos Therapeutics currently has an average rating of “Buy” and an average price target of $20.94.


https://www.thecerbatgem.com/2017/01/12/neos-therapeutics-inc-neos-stock-rating-upgraded-by-zacks-investment-research.html